Clinical Trial Update: Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating acalabrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: Seema Bhat | Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING